Ernexa Therapeutics Inc. Deferred Tax Liabilities, Tax Deferred Income
Ernexa Therapeutics Inc. (ERNA) had Deferred Tax Liabilities, Tax Deferred Income of $49.00 thousand as of 2016-12-31, per its 10-K filed 2018-03-09.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome · last filed 2018-03-09
- 2016-12-31: Deferred Tax Liabilities, Tax Deferred Income $49.00K.
| Period end | Deferred Tax Liabilities, Tax Deferred Income |
|---|---|
| 2016-12-31 | $49.00K 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |